Evaluation of Insecticide-treated Eave Nets and Window Screens for Malaria Control in Tanzania. (ITENs)

November 19, 2021 updated by: Ifakara Health Institute

A Household Randomized Control Trial of Insecticide-treated Eave Nets and Window Screens for Malaria Control in Chalinze District, Tanzania.

This is a household randomized trial of a new tool for house modification, Insecticide-Treated Eave nets (ITENs) in combination with insecticide-treated window screens (ITWS), coated with a dual active ingredient (dual AI): Deltamethrin at 3g AI/kg, which corresponds to 144 mg/m² and PBO synergist at 10g/kg which corresponds to 480 mg/m², as used in the so-called dual-AI LLIN or "resistance breaking" nets for resistance malaria vector control.

Four hundred and fifty (450) households with intact walls, opened eaves, and those without screens or nets on the windows in Chalinze district, Tanzania will be eligible and only recruited upon written informed consent. The households will be randomly allocated into two arms: one with ITENs and ITWS installed and the other without.

The primary outcome will be malaria parasite detection in household residents aged over 6 months old using a quantitative Polymerase Chain Reaction (qPCR) at approximately 12 months post-installation, coinciding with the long rainy season.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Detailed Description

In Tanzania, long-lasting insecticidal nets (LLINs) contributed to the high reduction of malaria in the last decade. However, malaria reduction in Tanzania is threatened due to increasing insecticidal resistance of malaria vectors, low access to LLIN, LLINs not lasting up to three years, and net usage compliance. Therefore, it is evident that an additional cost-effective vector control tool is required that may confer protection against resistant malaria vectors, protect every member of the household, requires little or less compliance to use after distribution, and lasts longer.

The proposed additional vector control tool for trial is the Insecticide-Treated Eave nets (ITENs) in combination with Insecticide Treated Window screens (ITWS) for house modification. The tool is coated with a dual active ingredient (dual AI): Deltamethrin at 3g AI/kg, which corresponds to 144 mg/m², and PBO synergist at 10g/kg which corresponds to 480 mg/m², which are coated at the same concentration in insecticide-treated nets that are already in use in the population to control pyrethroid-resistant mosquitoes. These can protect everyone in the house by blocking mosquito entry and killing mosquitos that contact them to protect everyone in the community.

In this trial, 450 households will be randomly allocated into two arms. One arm with ITENs & ITWS installed and the other without to serve as the control arm. The 450 households are recruited and assigned codes during baseline data collection. The assigned codes are randomized to either of the two arms by simple randomization in STATA and stratified by sub-village.

Approximately 6 months and 12 months post-installation, coinciding with the rainy seasons, clinical officers will screen for malaria parasites in household residents of over 6 months old (it is estimated that 4.4 persons reside in each household, thus approx. 1,800 persons will be screened for malaria per survey) in both arms and confirmation of malaria parasite will be done using qPCR analysis as the primary assessment of the primary outcome. As a point of care, SD Bioline Malaria Ag Pf/Pan rapid diagnostic test (RDT) as per Tanzanian guidelines will also be conducted on all household residents. Any participant (s) with an axillary temperature of 37.5 degrees (fever) and that test positive using mRDT will be considered as a clinical malaria case. All malaria-positive participants will be treated using free Artemether Lumefantrine (ALu). This drug is approved by the national guideline for the treatment of uncomplicated malaria.

Other secondary objectives are:

  • To evaluate malaria prevalence in households with ITENs & ITWS and those without at approximately 6 months post-installation, coinciding with the short rainy season.
  • To determine the prevalence of clinical malaria defined by an axillary temperature of 37.5 degrees and above (fever) and mRDT malaria positive cases at approximately 6 months and 12 months post-installation, coinciding with the rainy seasons.
  • To investigate the effect of ITENs and ITWS on the density of malaria vectors and nuisance (Culex quinquefasciatus) mosquitoes in the community at approximately 6 months and 12 months post-installation, coinciding with the rainy seasons using Centres for Disease Control (CDC) light traps.
  • To assess the number of fabric in meters and time of installing the intervention (feasibility of scaling-up ITENs and ITWS use) in local houses in the field during installation.
  • To assess the adverse effects of ITENs and ITWS in the community.
  • To determine the attrition and fabric integrity of ITENs and ITWS in the field post 6 months and 12 months of installation.
  • To determine the mortality induced by (bioefficacy) ITENs and ITWS on laboratory-reared mosquitoes post 12 months of installation.
  • To determine the insecticide retainment of ITENs and ITWS post 12 months of installation.
  • To assess the acceptability of ITENs and ITWS to the local community post 6 months and 12 months of installation.

Study Type

Interventional

Enrollment (Anticipated)

1800

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

      • Bagamoyo, Tanzania
        • Recruiting
        • Vector Control Product Testing Unit Facility
        • Contact:
        • Principal Investigator:
          • Zawadi Mboma, PhD
        • Sub-Investigator:
          • Olukayode Odufuwa, MSc
        • Sub-Investigator:
          • Sarah Moore, PhD

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

6 months and older (Child, Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Residents of study households' members.

Exclusion Criteria:

  • None residence.
  • Pregnant women.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: ITENs + ITWS
Deltamethrin at 3g AI/kg, which corresponds to 144 mg/m², and PBO synergist at 10g/kg which corresponds to 480 mg/m² are coated in ITENs and ITWS nets that will be installed to cover opened eaves and windows. This was manufactured by Moon Netting FZCO, United Arab Emirates.
A dual active ingredient (dual AI) Insecticide-Treated Eave nets (ITENs) in combination with Insecticide Treated Window screens (ITWS) for house modification.
No Intervention: Negative arm
The houses allocated NOT to receive ITENs and ITWS.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Prevalence of Plasmodium falciparum parasite.
Time Frame: Approximately 12 months post-installation, coinciding with the long rainy season.
Prevalence of plasmodium falciparum parasite measured by qPCR among residents over 6 months old in houses with ITENs & ITWS compared to houses without.
Approximately 12 months post-installation, coinciding with the long rainy season.

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Prevalence of Plasmodium falciparum parasite.
Time Frame: Approximately 6 months post-installation, coinciding with the short rainy season.
Prevalence of plasmodium falciparum parasite in households' residents of over 6 months old with ITENs & ITWS compared to those without using qPCR analysis.
Approximately 6 months post-installation, coinciding with the short rainy season.
Clinical malaria.
Time Frame: Approximately 6 months and 12 months post-installation, coinciding with the rainy seasons.
The prevalence of clinical malaria cases defined by an axillary temperature of 37.5 degrees (fever) and positive mRDT in houses with ITENs and ITWS compared to the houses without.
Approximately 6 months and 12 months post-installation, coinciding with the rainy seasons.
The density of malaria vectors and nuisance mosquitoes density.
Time Frame: Approximately 6 months and 12 months post-installation, coinciding with the rainy seasons.
Indoor density of malaria vector and nuisance mosquitoes in houses with ITENs & ITWS compared to houses without measured using Centres for Disease Control (CDC) light traps.
Approximately 6 months and 12 months post-installation, coinciding with the rainy seasons.
ITENs & ITWS fabric cost
Time Frame: Baseline (During installation of ITENs & ITWS)
The number of metres of material applied to houses.
Baseline (During installation of ITENs & ITWS)
ITENS & ITWS time duration
Time Frame: Baseline (During installation of ITENs & ITWS)
Time in hours to install the intervention.
Baseline (During installation of ITENs & ITWS)
Adverse effects
Time Frame: Approximately one month post installation.
The number of participants with perceived adverse effects from ITENs and ITWS.
Approximately one month post installation.
Attrition
Time Frame: Appriximately 6 months and 12 months post installation.
Determination of the physical presence of ITENs and ITWS in the field.
Appriximately 6 months and 12 months post installation.
Fabric integrity
Time Frame: Appriximately 6 months and 12 months post installation.
Determination of the number of holes in ITENs and ITWS in the field.
Appriximately 6 months and 12 months post installation.
The induced mosquito mortality of ITENs and ITWs on the population of laboratory-reared mosquitoes.
Time Frame: Approximately 12 months post installation.
The bioefficacy (% induced mosquito mortality) of ITENs and ITWS after field use through WHO bioassays.
Approximately 12 months post installation.
Insecticide retainment
Time Frame: Appriximately 12 months post installation.
The retention of deltamethrin and PBO in grams per kg will be assessed through high performance liquid chromatography.
Appriximately 12 months post installation.
Use of ITENs and ITWS
Time Frame: Approximately 6 months and 12 months post installation.
Community opinions of ITENs and ITWS will be sought through questionnaires and Focus Group Discussions.
Approximately 6 months and 12 months post installation.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Study Director: John Bradley, PhD, London School of Hygiene and Tropical Medicine

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

July 9, 2021

Primary Completion (Anticipated)

August 31, 2022

Study Completion (Anticipated)

September 30, 2022

Study Registration Dates

First Submitted

October 26, 2021

First Submitted That Met QC Criteria

November 7, 2021

First Posted (Actual)

November 18, 2021

Study Record Updates

Last Update Posted (Actual)

December 2, 2021

Last Update Submitted That Met QC Criteria

November 19, 2021

Last Verified

November 1, 2021

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

Data will be disseminated by a report to the sponsor, followed by peer-reviewed publications targeted towards consumers, scientists, and policy-makers. We will publish the results and data sets in open-access, indexed, peer-reviewed journals, making the findings and the data publicly available to all stakeholders. Data obtained from the study will be presented at international conferences and stakeholder meetings including the National Malaria Control Program, with priority given to the young scientists to practice their presentation and collaboration skills. At the end of the project, a meeting will be held to update the local community and the District Medical Officer (DMO), to present findings and answer any questions arising.

IPD Sharing Time Frame

Data will be available at the end of the trial once it is analysed and published.

IPD Sharing Access Criteria

Peer-reviewed open-source journals.

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL
  • SAP
  • ICF

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Malaria,Falciparum

Clinical Trials on ITENs + ITWS

Subscribe